Are you Dr. Cole?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 79 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
12697 E 51st St
Tulsa, OK 74146Phone+1 918-505-3200Fax+1 918-505-3253
Summary
- Dr. Scott Cole, MD is an oncologist in Tulsa, Oklahoma. He is currently licensed to practice medicine in Oklahoma, South Carolina, and Alabama. He is affiliated with Saint Francis Hospital, Ascension St. John Medical Center, and Stillwater Medical Center.
Education & Training
- Medical University of South CarolinaFellowship, Hematology and Medical Oncology, 2007 - 2010
- University of Alabama Medical CenterResidency, Internal Medicine, 2003 - 2006
- University of Oklahoma College of MedicineClass of 2003
Certifications & Licensure
- OK State Medical License 2010 - 2025
- SC State Medical License 2007 - 2011
- AL State Medical License 2004 - 2008
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Hospice and Palliative Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2013
Clinical Trials
- PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score Start of enrollment: 2012 May 01
- A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer Start of enrollment: 2015 Jul 07
Publications & Presentations
PubMed
- Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal C...Pedro Barata, Catherine Tangen, Melissa Plets, Ian M Thompson Jr, Vivek Narayan
Journal of Clinical Oncology. 2024-11-20 - 137 citationsA comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trialSumanta K. Pal, Catherine M. Tangen, Ian M. Thompson, Naomi S. Balzer-Haas, Daniel J. George
Lancet. 2021-02-20